NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 05/16/2025 at 12:30, 11 months 25 days ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials

NanoViricides NV-387 Financials Form 10-Q Phase II Trial
BRIEF

published on 05/14/2025 at 12:35, 11 months 27 days ago

NanoViricides Advances with Broad-Spectrum Antiviral Drug NV-387

Antiviral Drugs MPOX Treatment Measles Outbreak NV-387 Development Global Health Strategy
BRIEF

published on 05/14/2025 at 12:35, 11 months 27 days ago

NanoViricides progresse avec le médicament antiviral à large spectre NV-387

Médicaments Antiviraux Traitement MPox Épidémie De Rougeole Développement NV-387 Stratégie Mondiale En Matière De Santé
PRESS RELEASE

published on 05/14/2025 at 12:30, 11 months 27 days ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387

NanoViricides NV-387 Antiviral Nanomedicine Viral Infections
BRIEF

published on 05/08/2025 at 12:35, 1 year ago

Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NV-387 Clinical Trial Antiviral Drug Mpox Democratic Republic Of Congo
BRIEF

published on 05/08/2025 at 12:35, 1 year ago

Approbation de l'essai clinique de phase II du NV-387 de NanoViricides en RDC

NV-387 Essai Clinique Mpox Médicament Antiviral République Démocratique Du Congo
PRESS RELEASE

published on 05/08/2025 at 12:30, 1 year ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities

NanoViricides, CNES Approval, Phase II Clinical Trial, NV-387, MPox Disease
BRIEF

published on 04/29/2025 at 12:35, 1 year ago

Avancée potentielle dans le traitement de la rougeole : NanoViricides développe un médicament antiviral

NanoViricides NV-387 Médicament Antiviral Traitement De La Rougeole Maladie Endémique
BRIEF

published on 04/29/2025 at 12:35, 1 year ago

Potential Breakthrough in Measles Treatment: NanoViricides Develops Antiviral Drug

NanoViricides NV-387 Antiviral Drug Measles Treatment Endemic Disease
PRESS RELEASE

published on 04/29/2025 at 12:30, 1 year ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides, Inc. provides details on its Measles drug development program targeting the endemic potential of the virus in the USA and the effectiveness of their broad-spectrum antiviral drug NV-387

NV-387 NanoViricides Inc. Broad-spectrum Antiviral Measles Drug Development Vaccination Decline

Accesswire

Published on 05/09/2026 at 01:55, 2 days 4 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 2 days 4 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 2 days 4 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 6 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 2 days 7 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 14 hours 2 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 16 hours 7 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 18 hours 22 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 11 hours ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 9 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days 10 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 10 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 11 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 11 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 11 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE